Lv43
548 积分 2025-08-28 加入
Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients
2小时前
待确认
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
7天前
已完结
Antibody-drug conjugates in HER2-positive breast cancer
8天前
已完结
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
8天前
已完结
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(†)
9天前
已完结
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>
10天前
已关闭
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
10天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
17天前
已完结
Laboratory Testing of Direct Oral Anticoagulants
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
皖公网安备34019202002308
